Corporate News Report – Lisata Therapeutics (LSTA)
Lisata Therapeutics (ticker: LSTA) advanced 4 % during a 24‑hour trading window that closed at 09:39 PM Central Europe on Wednesday, 21 April 2026. At the moment, one share is available for purchase at USD 1.01 on the major exchanges.
The company’s shares are presently circulating in a total supply of 9 million units, yielding a market capitalization of roughly USD 9 million. In the last 24 hours, approximately USD 118.2 k of Lisata shares were traded. Compared with the close at the end of the previous month, the share price has slipped ‑33.33 %.
For context, the 200‑day simple moving average sits at USD 3.03, a figure that is more than three times the current price. The most recent peak within the past year was USD 5.07, reached on 10 March 2026, while the lowest point recorded in that span was USD 0.96, on 19 October 2026.
Market Performance of Peer Companies
| Company | Ticker | 24‑hour movement | Current price | Market cap | Notable metrics |
|---|---|---|---|---|---|
| Avalon | AWX | −0.38 % | USD 2.60 | USD 10.2 million | P/E = 8.61 |
| Biovie | BIVI | −9.49 % | USD 1.26 | USD 10.3 million | Phase 2 SUNRISE‑PD trial results |
| Palatin | PTN | −7.85 % | USD 5.74 | USD 10.7 million | – |
| Intensity Therapeutics | INTS | −0.30 % | USD 3.24 | USD 10.7 million | – |
| In8bio | INAB | +4.59 % | USD 1.05 | USD 10.8 million | – |
Biovie’s recent data highlights progress in its investigational drug, bezisterim. The Phase 2 SUNRISE‑PD trial, presented at the American Neurological Association meeting, involved 57 patients over 12 weeks. Patients receiving bezisterim displayed significant improvements in both motor and non‑motor Parkinson’s disease symptoms, especially those with higher baseline systemic inflammation. The drug was well tolerated, with fewer treatment‑emergent adverse events than placebo, reinforcing the company’s commitment to advancing a potential therapy for unmet needs in Parkinson’s disease.
About Lisata Therapeutics
Lisata Therapeutics, Inc. is a biopharmaceutical firm focused on developing therapies for cardiovascular and autoimmune disorders. The company operates on a global scale and is listed on Nasdaq. For further details regarding Lisata’s product pipeline and corporate initiatives, interested parties may visit the company’s website at www.caladrius.com .